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Summary. Serum and bone marrow from 21 patients with 
rheumatoid arthritis (RA) were studied in order to estab- 
lish the pathogenetic role of interleukin-6 (IL-6) in ane- 
mia of chronic disease (ACD). Erythroid colony growth, 
using burst forming units of erythroblasts (BFUe) as a 
parameter, was impaired in ACD and not in nonanemic 
RA controls. Serum IL-6 was elevated in ACD and it 
correlated well with parameters ofdisease activity such as 
erythrocyte sedimentation rate and C-reactive protein. 
IL-6 addition to bone marrow cultures had inconsistent 
effects while anti-IL-6 addition resulted in impaired ery- 
throid colony growth, suggesting stimulatory effects of 
IL-6 produced in the medium, which may be masked by 
simultaneous production of cytokines with suppressive 
effects. It was concluded that elevated serum IL-6 in 
ACD reflects disease activity. It probably plays no patho- 
genetic role in ACD. Its stimulatory effects on erythroid 
growth might counteract suppressive effects of other in- 
terleukins. 
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Introduction 
Anemia is frequently seen in patients with active rheuma- 
toid arthritis (RA) [1]. Many causes of anemia re associ- 
ated with RA, such as deficiencies of iron [2], vitamin B12 
[3], and folic acid [4]. The most frequent type of anemia 
seen in RA, however, is the anemia of chronic disease 
(ACD) [5]. Many studies have been carried out to exam- 
ine pathogenesis of ACD in RA. Decreased iron release 
from the mononuclear phagocyte system (MPS) [6, 7], 
decreased iron absorption [8], and decreased erythropoi- 
etin responsiveness to the anemia [9] have been claimed to 
* Tho whom offprint requests hould be sent at: Department of 
Rheumatology, Dr. Daniel den Hoed Clinic, Groene Hilledijk 301, 
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play a role in the pathogenesis of ACD. More recently, 
investigations have also been concerned with a possible 
role of interleukins as mediators. For instance, inter- 
leukin-1 (IL-I) and tumor necrosis factor (TNF) were 
able to suppress erythropoiesis in vitro [10, 11]. 
Interleukin-6 (IL-6) is a monokine with biological ac- 
tivities related to inflammatory esponses [12, 13]. IL-6 
levels were elevated in serum and synovial fluid of pa- 
tients with active RA [14, 15]. About the effects of IL-6 
on bone marrow only few data exist [16]. 
Here we report experiments dealing with a possible 
role of IL-6 in determining anemia in RA. 
Patients and methods 
Serum from 21 patients (6 male, 15 female) with classical or definite 
RA [17] and bone marrow from 21 RA patients and 5 normal 
donors were studied after obtaining patients' written informed con- 
sent. RA patients were divided into two groups: group I consisted 
of 9 nonanemic patients and group II of 12 patients with ACD. 
Patients who had iron, vitamin B12, or folic acid treatment recently, 
or patients with a present or past ulcer history, hematuria, hyperme- 
norrhea, positive occult fecal blood test, hemolysis, iron, vitamin 
B12, or folic acid deficiency, or decreased creatinine clearance were 
excluded. Patients using corticosteroids or cytostatic drugs were 
also excluded. Mean overall disease duration had been 7 years 
(range 4-17); 74% used long-acting antirheumatic drugs and 88% 
used nonsteroidal ntiinflammatory drugs. Mean age was 64 years. 
These characteristics did not differ between groups I and II. 
Laboratory procedures. Hemoglobin (Hb), hematocrit (Ht), reticu- 
locytes, and ferritin and erythrocyte sedimentation rates (ESR) were 
measured using standard laboratory procedures. C-reactive protein 
(CRP) was assessed using immunodiffusion techniques and Rose 
test using sensitized sheep erythrocytes. A titer over 1/32 was con- 
sidered positive [18]. 
IL-6 in serum was measured in the B9 assay [19]. Serum was 
heated for 30 min at 56 °C and a titration was added to 5000 B9 cells 
and compared with standard IL-6 preparation. After 3 days prolif- 
eration was measured by thymidine incorporation; 1 U/ml is a con- 
centration that leads to one-half maximal proliferation. In 100 
healthy individuals erum levels were less than 10 U/ml. 
Bonel marrow was aspirated after posterior superior iliac crest 
puncture. Iron content was measured using Perls' Prussian blue 
128 
Table I. Erythrocyte parameters, parameters ofdisease activity, IL-6, and burst forming units (BFUe) per 10 5 cells in RA patients without 
anaemia nd ACD 
Hb Ht Retics BFUe ESR CRP Rose IL-6 Ferritin 
(mmol/) (L/L) (0/00) (col. per (mm/h) (mg/1)  reciprocal (~tg/1) 
10 s cells) titer 
NonanemicRA 7.9 0.39 17 260 34 8 32 0 39 
(n=9) (7.5-8.3) (0.35-0.42) (5-39) (215-391) (21-60) (4-45) (0-256) (0-11) (12-86) 
ACD RA 6.6* 0.31 * 17 191 ** 74* 62** 32 29 *** 108 ** 
(n= 12) (5.4 7 .3 )  (0.28-0.34) (1-28) (123-108) (40-105) (10-121) (0-256) (0-82) (39-410) 
• P<0.001, ** P<0.01, ***P<0.10. Values are expressed as median with range 
Table 2. Standard BFUe count (no addition; counts per 10 5 cells incubated) and absolute (abs) and relative (%) change in BFUe count after 
addition of IL-6 (1000 U/ml) and anti-IL-6 (1000 (U/ml) to the cultures in controls, nonanemic, and anemic RA patients 
Addition Controls (n = 5) Nonanemic RA (n = 3) ACD RA (n = 8) 
abs % abs % abs % 
None 356 100 246 100 173 100 
(254-396) (242-282) (12-440) 
IL-6 266* 80+20 * 294 111 +2* 155 91 +21 
(225-266) (57-105) (168-318) (109-113) (6-471) (83-107) 
Anti-IL-6 219"* 72_+16"** 228* 86_+10" 135" 72_+13"** 
(168-361) (55 -92) (180-244) (74-99) (8-329) (43 -83) 
* P<0.10, ** P<0.05, *** P<0.01 ; difference compared with standard BFUe count. Values expressed as median with range (percentages 
as mean and standard eviation 
staining. A stainable iron content of 0-1 was considered to signify 
iron deficiency [20]. 
A cell suspension was prepared from 20 ml bone marrow col- 
lected in Hanks' balanced salt solution (HBSS) with heparin diluted 
in HBSS and layered over a Ficoll gradient (1.077 g/cm 2, Nyeomed, 
Oslo, Norway). After centrifugation the mononuclear cells were 
harvested, washed twice in HBSS, and resuspended inHBSS [21]. A 
cell suspension of 105 cells was added to a mixture of Iscove's 
mediated Dulbecco medium (IMDM; 0.4 ml) 2% methylcellulose, 
0.3 ml fetal calf serum, 0.1 ml mixture (containing BSA, transferrin 
lecithin, sodium selenite, and 2-mercaptoethanol), and0.015 ml ery- 
thropoietin 1 U/L). This volume was divided over four Petri dishes 
which were incubated at 37°C and 100% humidity in an environ- 
ment of 5 % CO 2 in air. Burst forming units of erythroblasts (BFUe; 
containing 50 or more cells) were counted after 14 days. 
In three patients from group I, eight from group II, and in five 
normal donors IL-6 (1000 U/ml) and anti-IL-6 (1000 U/ml; synthe- 
sized by using a recombinant DNA technique; Central Laboratory 
of the Netherlands Red Cross and Blood Transfusion Service, Am- 
sterdam, The Netherlands) were added to the BFUe cultures to 
evaluate their effects on in vitro erythropoiesis. In seven patients 
(two in group I; five in group II) twice the amount of IL-6 or 
anti-IL-6 was added. 
Stat&ties. Student's t-test was used for normally distributed ata 
and the Mann-Whitney U-test was used for nonparametrical d ta. 
Data were correlated using Spearman's coefficient of correlation. A 
P-value of less than 0.05 was considered significant. 
This protocol was accepted by the Medical Ethics Committee of 
the Department of Rheumatology of the Dr. Daniel den Hoed 
Clinic. 
Results 
Parameters of erythropoiesis, disease activity and IL-6 
in RA patients without and with anemia 
The BFUe count was significantly ower in group II com- 
pared with group I (Table 1). Reticulocytes did not differ 
between the two groups. 
The ESR and CRP were significantly higher in group 
II. Hb correlated negatively with ESR ( r=-0 .71 ;  
P<0.001)  and CRP ( r=-0 .68 ;  P<0.005) .  The BFUe 
count correlated negatively with ESR ( r=-0 .65 ;  
P>0.005)  and CRP ( r= 0.66; P<0.01) .  No differences 
in Rose titer were found. 
Serum IL-6 tended to be higher in group II. IL-6 
correlated positively with ESR (r = 0.46; P < 0.025) and 
CRP (r = 0.52; P< 0.025) and negatively with Hb (r = 
-0.41; P<0.05)  but not with BFUe. 
Effects of addition of IL-6 and anti-IL-6 to 
bone marrow cultures (Table 2) 
The BFUe count was higher in controls compared with 
ACD patients (P < 0.05). The difference between controls 
(healthy donors) and nonanemics was not significant. 
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IL-6 addition slightly inhibited BFUe count in con- 
trols but stimulated growth in nonanemics. In seven cul- 
tures twice the amount of IL-6 was added (two controls, 
five ACD; not shown). Mean percentual BFUe count was 
109% + 18% compared with control BFUe count. 
Anti-IL-6 addition inhibited BFUe count in all 
groups, most pronounced in controls and ACD. Dou- 
bling the amount of anti-IL-6 added had no further in- 
hibitory effect on BFUe count (mean 82 _+ 16%; P < 0.01; 
not shown). 
Discussion 
We evaluated whether in vitro erythroid colony growth 
was reduced in patients with RA and ACD and examined 
a potential pathogenetic role of IL-6 in ACD. 
Erythroid colony growth, measured by BFUe count, 
was impaired in patients with RA and ACD and not in 
nonanemic RA patients. Reticulocyte count was the same 
in nonanemic and anemic RA patients, which further 
points to an inadequate bone marrow response in the 
anemia. A inverse correlation was found between 
parameters of RA activity, i.e., ESR and CRP and BFUe 
count and Hb. It therefore appears that RA activity de- 
termines the degree of anemia in ACD by inhibition of 
erythroid growth at stem cell level. Others have also de- 
scribed an inverse relationship between Hb and RA dis- 
ease activity [9]. Defective rythropoietin response to the 
anemia is claimed to contribute to the pathogenesis of 
ACD [9], while others point to suppressive effects of in- 
terleukins uch as interleukin-1 and tumor necrosis factor 
alpha (TNFc 0 on erythroid colony growth [10, 11]. 
IL-6 is a monokine with biological activities related to 
inflammatory responses [12, 13]. It was shown that IL-6 
levels were evaluated in serum and synovial fluid of pa- 
tients with active RA [14, 15]. In another study among 
patients with systemic lupus erythematosus it was also 
found that IL-6 correlated with CRP, although in these 
patients, in contrast o RA patients with active RA, se- 
rum levels were low [22]. It was suggested that IL-6 deter- 
mined CRP response. 
We found that serum IL-6 levels correlated positively 
with parameters of RA activity, i.e., ESR and CRP, 
which confirms its role in the inflammatory response in 
RA. Serum IL-6 correlated negatively with Hb and it was 
elevated in most of our ACD patients. Since we found an 
inverse relationship between RA disease activity and 
BFUe count, it was assumed that IL-6 might be a media- 
tor of impaired erythroid colony growth. 
IL-6 and anti-IL-6 antibodies were added to the bone 
marrow cultures in order to establish their effects on ery- 
throid colony growth. IL-6 addition resulted in a slight 
inhibition of BFUe growth in controls and ACD. In 
nonanemic ontrols in contrast it stimulated erythroid 
growth. After addition of anti-IL-6 antibody erythroid 
colony growth was impaired in all cases. Addition of 
twice the amount of IL-6 or anti-IL-6 did not increase the 
in vitro effects in either case. From these data it is con- 
cluded that antML-6 might have inhibitory effects of ery- 
throid colony growth. Probably IL-6 is produced by bone 
marrow cells. Possibly the stimulatory effects of locally 
produced IL-6 are neutralized by the addition of anti- 
IL-6 while IL-6 addition in the amount used here has no 
further effects on erythroid growth. The anti-IL-6 anti- 
body specificity is not entirely known. So although a 
consistent inhibition or erythropoiesis occurred it is not 
known whether antibodies with a similar isotype as anti- 
IL-6 might have caused the same suppression. If so it 
could also be that, for instance, effects of other cytokines 
are inhibited. IL-6 production probably is enhanced by 
IL-1, and TNF [23-25]. It is therefore not unlikely that 
IL-6 production is stimulated by IL-1 and TNF produc- 
tion in the marrow cultures. These cytokines inhibit ery- 
thropoiesis [10, 11] masking potential stimulative ffects 
of IL-6. It might even be speculated that IL-6 induces 
production of other cytokines with suppressive effects on 
erythroid growth. This might explain the inconsistent ef- 
fects of IL-6 addition in the different groups. IL-6 has 
been found to trigger primitive hematopoietic cells into 
cell cycle in vitro, most pronounced in the presence of IL-3 
[16], whereas others found that IL-6 had no effects on 
erythroid growth in acute myeloblastic leukemia [26]. It 
is therefore unlikely that IL-6 - shown to be raised in 
serum of RA patients with ACD - is a cause of ACD in 
RA. In contrast, it might be speculated, based on the 
findings of anti-IL-6 addition, that IL-6 might counteract 
suppressive effects of other interleukins such as IL-1 [10] 
and TNFe [11], which enhance IL-6 production [24-26], 
on erythroid colony growth. 
In conclusion, these preliminary data show that ery- 
throid colony growth is impaired in ACD. Serum IL-6 
correlated with RA activity and was elevated in ACD but 
it had no pathogenetic role in ACD since in vitro its 
antibody rather had suppressive than stimulatory effects 
on erythroid growth while the effects of IL-6 addition 
were inconsistent. 
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